fbpx

NeoDynamics – Full year report and latest development

NeoDynamics - Full year report and latest development 21 FebruarFeb 2022 12:30 - 13:00 Europe/CopenhagenOnline Event

NeoDynamics – Full year report and latest development

Neodynamics will release full year and fourth quarter result on the 16th of February. Listen to CEO Anna Eriksrud on the 21st of February wrap-up the most important events in 2021 and what to expect in 2022. Anna Eriksrud will be joined by the new CFO Aaron Wong.

Key events in 2021:

  • NeoDynamics presented a scientific abstract at the annual surgery conference ABS, Association of Breast Surgeons, in Birmingham, which describes how the company’s FlexiPulse needle surpasses standard biopsy in preclinical models by almost 300 percent in terms of volume.
  • At mid-year, about 30 clinics with radiology teams in Sweden, the United Kingdom, Germany and other German-speaking countries in Europe had had workshops with the biopsy system NeoNavia
  • Hermann-Josef-Hospital in Erkelenz, a university hospital within the University of Aachen, became the first German hospital to order the NeoNavia biopsy system. Additional high-profile clinics in Germany and Switzerland placed orders for needles.
  • Patents were issued in the United States for the FlexiPulse needle.
  • NeoNavia was demonstrated at scientific congresses in Austria and Switzerland. Doctors received the system very well at the congresses which marked a return to a more normal market.
  • NeoDynamics received orders from four high-profile clinics in Germany and Switzerland for the NeoNavia biopsy system. This shows that clinicians are moving to the next step in evaluating the system and are moving towards incorporating it into their clinical practice.
  • NeoDynamics started a subsidiary in Germany, NeoDynamics GmbH, to grow in this important market for the company's innovative biopsy system NeoNavia
  • The first results from the German PULSE study were presented at the prestigious British Society of Breast Radiology (BSBR) annual scientific meeting. The study shows that NeoNavia can be used successfully and with a low frequency of side effects for sampling in the axilla.
  • NeoDynamics appointed Aaron Wong as CFO
  •  New data from NeoDynamics PULSE study accepted for presentation at major US breast imaging conference
  • New data from NeoDynamics PULSE study accepted for presentation at major US breast imaging conference

Key events in 2022:

  • New data from NeoDynamics PULSE study accepted at major US imaging conference.
About the Company:

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. Neodynamics first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients.

Disclaimer: HC Andersen Capital receives payment from NeoDynamics for a Digital IR / Corporate Visibility subscription agreement.

Deltag her

Du vil blive videresendt til en ekstern tilmeldingsside. 

Information

NeoDynamics - Full year report and latest development 21 FebruarFeb 2022 12:30 - 13:00 Europe/Copenhagen
NeoDynamics - Full year report and latest development Online Event
Aktier